Scientific Advisors

Blend has assembled a world-class team of scientific advisors that includes recognized experts in the fields of cancer metabolism, oncology, drug discovery, medicinal chemistry, nanomedicine, nanoparticle engineering, and drug delivery. These advisors work closely with Blend scientists to identify research directions as well as optimal combinations for Blend’s integrative medicines.

Dr. Ausiello is an internationally recognized scientist and leader in academic medicine noted for his contributions to the field of epithelial biology in the areas of membrane protein trafficking, ion channel regulation, and signal transduction. As Chief of Medicine at Massachusetts General Hospital (MGH), a position he has held since 1996, he leads one of the strongest departments of medicine in the country, with a clinical, research, and education budget exceeding $600 million annually. He is closely involved with the Partners HealthCare System, which links the resources of MGH, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute to provide comprehensive health care. Dr. Ausiello has published more than 100 scientific papers, chapters, and textbooks. He is an elected member of the National Academy of Science and the National Institute of Medicine. He received a B.S. from Harvard College and an M.D. from the University of Pennsylvania.

Dr. Barton’s research has focused on recognition and reactions of DNA, using transition metal complexes to probe this chemistry. Her electron transfer chemistry has been applied in the development of DNA-based sensors and may be important for long range signaling of DNA repair. Barton received the A.B. at Barnard College and a Ph.D. in Inorganic Chemistry at Columbia University. After a postdoctoral fellowship at Bell Laboratories and Yale, she joined the faculty at Hunter College. She then moved first to the chemistry faculty at Columbia University in 1983, and to Caltech in 1989. In 2009 she began her term as Chair. Barton has authored more than 300 scientific articles and has trained over 100 students and postdoctoral associates. She has received numerous honors including a MacArthur fellowship and membership in the American Philosophical Society, the National Academy of Sciences, and the Institute of Medicine. In 2011, she was awarded the National Medal of Science. She has served as a member of the Board of Directors of the Dow Chemical Company since 1993.

Dr. Farokhzad is an internationally recognized expert in the field of nanomedicine who pioneered the high-throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. The combinatorial nanoparticle self-assembly technologies he developed or co-developed formed the foundation and launch of Blend Therapeutics and two other clinical-stage biotechnology companies, BIND Biosciences and Selecta Biosciences, where he serves, respectively, as a Director and as Vice Chairman on the Board of Directors. Dr. Farokhzad is the author of more than 75 scientific papers and a named inventor on more than 65 issued or pending patents. He was among the Nano50 recipients of 2007 by NASA Nanotech Briefs; in 2009 he received the All Star Distinguished Achievement Award from Mass High Tech for his contributions to the life sciences industry; in 2012 he was elected to the College of the Fellows of the American Institute of Medical and Biological Engineering. Dr. Farokhzad holds M.A. and M.D. degrees from Boston University School of Medicine. He completed his postdoctoral training at Brigham and Women’s Hospital and Harvard Medical School and his clinical and research training in the laboratory of Dr. Robert Langer at MIT.

Dr. Kantoff’s research focuses on the molecular basis of genitourinary cancers, the genetics of prostate cancer, and developing improved treatments for prostate cancer, kidney cancer, bladder cancer, and testicular cancer. He has published more than 250 research articles and serves as a consultant for a number of biotechnology companies. He received a B.S. in Biology and an M.D. from Brown University. He completed his internship/residency and chief residency in Internal Medicine at New York University–Bellevue Hospital and completed his fellowship training in Medical Oncology at Dana-Farber Cancer Institute, Harvard Medical School.

Dr. Klibanov’s research has focused on enzyme chemistry and biotechnology, drug delivery and formulation, stability and stabilization of pharmaceutical proteins, and antimicrobial materials. He has authored nearly 300 scientific papers, is a named inventor on 18 issued U.S. patents, and is a member of nine journal editorial boards. He is an elected member of the U.S. National Academy of Sciences and the National Academy of Engineering and a founding Fellow of the American Institute for Medical and Biological Engineering. Dr. Klibanov is the recipient of numerous prestigious awards from the American Chemical Society including the Leo Friend Award, the Ipatieff Prize, the Marvin J. Johnson Award, and the Arthur C. Cope Scholar Award, as well as the International Enzyme Engineering Prize. He is a co-founder of five biotechnology companies and has served as a scientific advisor/consultant for numerous pharmaceutical, chemical, and medical device companies. Dr. Klibanov received an M.S. in Chemistry and a Ph.D. in Chemical Enzymology, both from Moscow University in Russia.

Dr. Langer is renowned for his pioneering contributions in the use of biomaterials in drug delivery and tissue engineering. He is the author of more than 1,175 scientific papers and a named inventor on more than 800 issued or pending patents worldwide; his patents have been licensed or sublicensed to more than 220 pharmaceutical, chemical, biotechnology, and medical device companies. Dr. Langer is the recipient of more than 210 major awards, including the National Medal of Science, the highest civilian honor bestowed by the United States; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize in the field of engineering; the Millennium Prize, the world’s largest technology prize; the Priestley Medal, the highest award bestowed by the American Chemical Society; and the Lemelson-MIT prize, the world’s largest prize for invention. He is the most cited engineer in history and is one of few individuals to have been elected to all three U.S. national academies—the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. He is the co-founder of more than 20 companies, including BIND Biosciences, Selecta Biosciences, Momenta, and Transform. Dr. Langer holds a B.S. from Cornell University and an Sc.D. from MIT, both in Chemical Engineering.

Dr. Lippard is recognized as a major international figure in the areas of bioinorganic and medicinal inorganic chemistry, with expertise that spans the fields of inorganic chemistry, biological chemistry, and neurochemistry. His research is focused on the interface of inorganic chemistry and biology, with an emphasis on advancing understanding of and improving platinum anticancer drugs. Prior to joining MIT, Dr. Lippard was Professor of Chemistry at Columbia University. He is the author of more than 800 scientific papers and is the recipient of numerous prestigious awards, including the National Medal of Science. Dr. Lippard is an elected member of the National Academy of Sciences, the National Institute of Medicine, and the American Academy of Arts and Sciences. He received a B.A. in Chemistry from Haverford College and a Ph.D. in Inorganic Chemistry from MIT before joining the faculty of Columbia University in 1966 as an Assistant Professor. He moved to MIT as full Professor at the end of 1982, where he was Head of the Chemistry Department from 1995-2005.

Dr. Andrian is an internationally recognized expert in the basic exploration of immune responses to exogenous and endogenous challenges such as infections, tumors, and immune diseases. Using in vivo microscopic imaging technologies developed in his laboratory, Dr. von Andrian has identified how different immune cells migrate and communicate in living tissues and how immunomodulatory drugs can be designed to control and modify these events. He co-founded Selecta Biosciences to apply these insights to the development of rationally engineered immunobiologics for the treatment and prevention of human diseases. Dr. von Andrian is a member of the European Academy of Sciences and several professional societies from which he has received awards for outstanding research, including the Amgen Outstanding Investigator Award, the Henry Pickering Bowditch Award, the BD Biosciences Investigator Award, and the Eugene Landis Award. He holds an M.D. from Ludwig-Maximillians University (Germany) and completed postdoctoral studies at the La Jolla Institute for Experimental Medicine and, subsequently, at Stanford University in California.

Dr. Zetter is an internationally recognized leader in the research of tumor angiogenesis, progression, cancer diagnosis, and cancer metastasis. In 1979, he and Dr. Judah Folkman showed that endothelial cells in large blood vessels are different from those in capillaries, marking a milestone in angiogenesis research. The following year, Dr. Zetter went on to identify the first angiogenesis inhibitor, interferon-alpha. His research currently focuses on tumor metastasis and on identifying diagnostic and prognostic markers to guide treatment decisions, including a new prognostic marker for prostate cancer. Dr. Zetter has received numerous national and international awards for his work in the field of cancer research, including a Faculty Research Award from the American Cancer Society and two MERIT awards from the U.S. National Cancer Institute. He serves as a scientific advisor or consultant to a number of biotechnology and pharmaceutical companies. Dr. Zetter received a Ph.D. from the University of Rhode Island and completed postdoctoral fellowships at MIT and the Salk Institute.